Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial Results Conference Call on the Web

Webcast Alert: Allos Therapeutics, Inc. Announces Third Quarter 2003 Financial
Results Conference Call on the Web 


WESTMINSTER, Colo., Oct. 31  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. 
announces the following Webcast:

   What:     Allos Therapeutics Third Quarter 2003 Financial Results
             Conference Call Webcast

   When:     November 6, 2003 @ 11:00 AM EST

   Where:    http://www.firstcallevents.com/service/ajwz392805477gf12.html

   How:      Live over the Internet -- Simply log on to the web at the
             address above or
             Live Call:  Domestic:  1-800-915-4836;
             International:  1-973-317-5319; no passcode required.

   Replay:   Domestic: 1-800-428-6051; International: 1-973-709-2089;
             Passcode: 311459.
             The replay will be available for five business days following
             the call.

   Contact:  Laurel Beltran, 303-426-6262, 



Allos Therapeutics, Inc. is a biopharmaceutical Company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
Company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor
tissues and enhance the efficacy of standard radiation therapy.  In addition,
Allos is developing PDX, a novel small molecule cytotoxic injectable anti-folate
(DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma
and non-Hodgkin's lymphoma.  For more information, please visit the Company's
web site at: http://www.allos.com/ .

(Minimum Requirements to listen to broadcast: The Windows Media Player software,
downloadable free from
http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a
28.8Kbps connection to the Internet.  If you experience problems listening to
the broadcast, send an email to ). 

PRNewswire-FirstCall -- Oct. 31

DATASOURCE: Allos Therapeutics, Inc.



Web site:  http://www.allos.com/ 

Copyright